IXAKA
Ixaka is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease. Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action. Ixaka’s technologies – concentrated multi-cell therapies and targeted nano-particles – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders.
IXAKA
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.ixaka.com
Total Employee:
51+
Status:
Active
Contact:
+44 203 7007 480
Email Addresses:
[email protected]
Total Funding:
72.66 M USD
Technology used in webpage:
Viewport Meta SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Google Universal Analytics Font Awesome Apache
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Healx
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
HeartBeat.bio
HeartBeat.bio is a privately funded drug discovery company focusing on the development of a high-throughput 3D screening platform.
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
PBUH Medicine
Hijama UK offered by PBUH Medicine is utilized to maintain the general well being of the human beings.
Current Advisors List
Current Employees Featured
Founder
Investors List
ZenPharma Limited
ZenPharma Limited investment in Venture Round - Ixaka
Innovate UK
Innovate UK investment in Grant - Ixaka
Innovate UK
Innovate UK investment in Grant - Ixaka
ZenPharma Limited
ZenPharma Limited investment in Series A - Ixaka
ZenPharma Limited
ZenPharma Limited investment in Seed Round - Ixaka
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-12 | Ixaka Appoints Karen Miller as Chief Scientific Officer |
Official Site Inspections
http://www.ixaka.com
- Host name: 172.67.216.95
- IP address: 172.67.216.95
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ixaka"
Home - Rexgenero
Ixaka strengthens IP Portfolio for its in vivo gene delivery platform and multi-cell therapy with key European and US patents; Ixaka (formerly Rexgenero) launches as an integrated cell and …See details»
Ixaka (formerly Rexgenero) launches as an integrated …
London, UK, 18 January 2021: Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The Company’s shareholders have funded the business with over £40 …See details»
Ixaka (formerly Rexgenero) Launches as an Integrated …
Jan 18, 2021 · LONDON-- (BUSINESS WIRE)--Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The Company’s shareholders have funded...See details»
Ixaka (formerly Rexgenero) launches as an integrated cell and …
Ixaka has offices in London, UK with R&D and manufacturing operations in Seville, Spain and Paris, France and additional manufacturing capability in Frankfurt, Germany. For more …See details»
Ixaka - LinkedIn
Ixaka (formerly Rexgenero) is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease.See details»
Ixaka - Crunchbase Company Profile & Funding
Ixaka is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease. Our proprietary technologies enhance the inherent …See details»
Ixaka (formerly Rexgenero) Launches as an Integrated Cell
Jan 18, 2021 · Ixaka has offices in London, UK with R&D and manufacturing operations in Seville, Spain and Paris, France and additional manufacturing capability in Frankfurt, Germany. For …See details»
Ixaka Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Ixaka. Use the PitchBook Platform to explore the full profile.See details»
Ixaka (formerly Rexgenero) launches as an integrated cell and …
London, UK, 18 January 2021: Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The Company’s …See details»
Ixaka - Org Chart, Teams, Culture & Jobs - The Org
View Ixaka's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
CELTIC-19 Granted Advanced Therapy Medicinal …
Mar 8, 2022 · CELTIC-19 – Ixaka’s targeted nanoparticle for CD19 haematological malignancies – has been granted Advanced Therapy Medicinal Product (ATMP) classification by the European Medicines Agency (EMA).See details»
Ixaka Expands IP Portfolio to Enable Use of Targeted Nanoparticle
Mar 21, 2022 · LONDON-- ( BUSINESS WIRE )--Ixaka Ltd, an integrated cell and gene therapy company, today announces an expansion of its IP portfolio to allow a broad range of …See details»
Ixaka and Minaris Regenerative Medicine Sign Tech Transfer
Jul 14, 2022 · London, UK and Munich, Germany - June 27, 2022 - Ixaka Ltd, an integrated cell and gene therapy company, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading …See details»
Ixaka strengthens IP Portfolio for its in vivo gene ... - Rexgenero
Feb 8, 2021 · Ixaka’s in vivo gene delivery platform enables therapeutic cells to be targeted and genetic modifications to be made directly within a patient’s body. The gene delivery platform is …See details»
Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and …
Jun 27, 2022 · Ixaka has offices in London, UK with R&D and manufacturing operations in Seville, Spain and Paris, France and additional manufacturing capability in Frankfurt, Germany. …See details»
Alaya.bio Acquires Key Assets From Ixaka France, Accelerating the ...
Oct 20, 2023 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Alaya.bio, an in vivo gene delivery biotech company, announces today the acquisition of all assets previously owned by Ixaka …See details»
Ixaka's cell therapy clears early phase 3 data review
Sep 10, 2021 · Ixaka, the biotech formerly known as Rexgenero, is testing that hypothesis in a clinical trial that is enrolling 78 patients with CLI and randomizing them to receive an infusion …See details»
Ixaka (formerly Rexgenero) launches as an integrated cell and …
LONDON, UK I January 18, 2021 I Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The Company’s …See details»
Ixaka announces positive interim Phase 3 clinical trial data for its ...
Sep 8, 2021 · Ixaka has offices in London, UK with R&D and manufacturing operations in Seville, Spain and Paris, France and additional manufacturing capability in Frankfurt, Germany. For …See details»
Ixaka’s cell therapy clears early phase 3 data review
Sep 18, 2021 · Ixaka, the biotech formerly known as Rexgenero, is testing that hypothesis in a clinical trial that is enrolling 78 patients with CLI and randomizing them to receive an infusion …See details»